Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Creabilis Announces New Appointments to its Scientific Advisory Board

Published: Monday, July 29, 2013
Last Updated: Monday, July 29, 2013
Bookmark and Share
Appointment of Professor Gil Yosipovitch and Professor Praveen Anand to Company’s Board.

Creabilis SA has announced that it has appointed Professor Gil Yosipovitch and Professor Praveen Anand to its Scientific Advisory Board.

Gil Yosipovitch is the newly announced Chair of the Department of Dermatology and Director of the Temple Itch Center at Temple University School of Medicine, and is one of the world’s renowned experts in pruritus. He was formerly Professor of Dermatology, Neurobiology and Anatomy and Regenerative Medicine at the Wake Forest University School of Medicine.

Professor Yosipovitch`s major clinical interest is pruritus, and his research focuses on the neurophysiology of itch. He chaired the first International Workshop for the Study of Itch in Singapore in 2001 and is the founder and past president of the International Forum for the Study of Itch (IFSI), which is a multidisciplinary international association of clinicians and researchers dedicated to improving the understanding of itch.

Professor Yosipovitch serves on the Editorial board of seven dermatology journals including the Journal of the American Academy of Dermatology (JAAD), Experimental Dermatology and Acta Dermatol Venereol.

He has been awarded several prestigious awards including the Rothschild Foundation award, and the Leo Foundation award in 2012 for research on itch. He has an MD from the Sackler Faculty of Medicine at Tel- Aviv University, Israel.

Praveen Anand is Professor of Clinical Neurology and Head of the Centre for Clinical Translation at Hammersmith Hospital, Imperial College London, UK.

Professor Anand is an internationally recognized scientist and clinical researcher in chronic pain. His research focuses on the pathophysiological and molecular mechanisms in human sensory neuropathies and chronic pain syndromes.

Professor Anand has been involved in several collaborations with pharmaceutical companies that bridge the gap between pre-clinical developments and their successful clinical applications. This translational approach has guided the recent success of three novel pain drugs from the laboratory to Phase 2 trials for chronic neuropathic pain.

Professor Anand received his medical education at the Universities of Oxford and Cambridge. His post-graduate training was at the Hammersmith Hospital and the National Hospital for Neurology and Neurosurgery, Queen Square, London.

On the Advisory Board, Professors Anand and Yosipovitch join other leaders in their fields including Professor Jonathan Barker (Head of Department at St John’s Institute of Dermatology, King’s College London), Professor Carlo Pincelli (Chief of the Laboratory of Cutaneous Biology, Institute of Dermatology, University of Modena and Reggio Emilia, Italy) and Professor Lars French (Professor and Chair of the Department of Dermatology, University Hospital Zurich, Switzerland), and Regulatory and Pharmacology industry experts Dr Lee Simon and Dr Alan Bye.

Professor Gil Yosipovitch, commenting on his appointment, said: “I am very honoured to join the Creabilis Scientific Board. Chronic pruritus is a debilitating symptom of many diseases and yet there is an unmet need to develop specific topicals that address itch. Creabilis has delivered clinically meaningful Phase 2b data in pruritus with CT327 which suggests the product has the potential to make a real difference to the lives of patients suffering from the condition. I look forward to working with the experienced Creabilis team to help achieve this goal.”

Professor Praveen Anand, commenting on his appointment, said: “I’m delighted to join the Creabilis Scientific Board. Neuropathic pain is an area of significant unmet need. CT340, with its novel dual analgesic and anti-inflammatory mechanism of action and strong pre-clinical data has the potential to meet this need. Creabilis is at an exciting stage of its development, with CT327 in late stage development for chronic pruritus and CT340 IND-ready in neuropathic pain. Given the mechanistic similarities between pruritus and pain, I am excited to begin working with Creabilis to realize the potential of both CT340 and CT327.”

Professor Jonathan Barker, Chair of the Scientific Advisory Board said: “Professors Anand and Yosipovitch bring further world-class expertise to an outstanding Advisory Board which will allow the Board to provide key scientific and clinical advice to Creabilis. It is a reflection of the quality of Creabilis’ recent clinical data with CT327 in chronic pruritus, and pre-clinical data with CT340 in neuropathic pain, that we have been able to attract individuals of Gil and Praveen’s calibre to our Scientific Advisory Board.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Creabilis Announces Treatment of First Patients in its Phase 2b Trial of CT327
Phase 2b study of CT327 in patients with atopic dermatitis.
Monday, September 23, 2013
Creabilis Announces Headline Results of its Phase 2b Trial of CT327
Clinically and statistically significant reduction of chronic pruritus (itch) seen in psoriasis patients.
Friday, May 10, 2013
Creabilis Receives Prestigious Technology Strategy Board Biomedical Catalyst Award
£1.42m funding will drive development of new treatment for Atopic Dermatitis.
Tuesday, November 06, 2012
Creabilis Appoints Dr Simon Russell as Chief Business Officer
Dr Russell to maximize the commercial potential of Company’s products and technology.
Thursday, May 03, 2012
Creabilis Raises €15M ($20M) in Series B Fundraising Round
Funds to advance development of Creabilis’ first-in-class products.
Wednesday, October 05, 2011
Scientific News
Retractable Protein Nanoneedles
The ability to control the transfer of molecules through cellular membranes is an important function in synthetic biology; a new study from researchers at Harvard’s Wyss Institute for Biologically Inspired Engineering and Harvard Medical School (HMS) introduces a novel mechanical method for controlling release of molecules inside cells.
Leukemia’s Surroundings Key to its Growth
Researchers at The University of Texas at Austin have discovered that a type of cancer found primarily in children can grow only when signaled to do so by other nearby cells that are noncancerous.
Common Cell Transformed into Master Heart Cell
By genetically reprogramming the most common type of cell in mammalian connective tissue, researchers at the University of Wisconsin—Madison have generated master heart cells — primitive progenitors that form the developing heart.
‘Smelling’ Prostate Cancer
A research team from the University of Liverpool and the University of the West of England (UWE Bristol) has reached an important milestone towards creating a urine diagnostic test for prostate cancer that could mean that invasive diagnostic procedures that men currently undergo eventually become a thing of the past.
Genetic Mutation that Prevents Diabetes Complications
The most significant complications of diabetes include diabetic retinal disease, or retinopathy, and diabetic kidney disease, or nephropathy. Both involve damaged capillaries.
Criminal Justice Alcohol Program Linked to Decreased Mortality
Institute has announced that in the criminal justice alcohol program deaths dropped by 4.2 percent over six years.
Charting Kidney Cancer Metabolism
Changes in cell metabolism are increasingly recognized as an important way tumors develop and progress, yet these changes are hard to measure and interpret. A new tool designed by MSK scientists allows users to identify metabolic changes in kidney cancer tumors that may one day be targets for therapy.
Improving Regenerative Medicine
Lab-created stem cells may lack key characteristics, UCLA research finds.
Tick Genome Reveals Secrets of a Successful Bloodsucker
NIH has announced that decipher the genome of the blacklegged tick which could lead to new tick control methods.
"Dark Side" of the Transcriptome
New approach to quantifying gene "read-outs" reveals important variations in protein synthesis and has implications for understanding neurodegenerative diseases.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!